ABSTRACT
Methotrexate-related malignant lymphoma (MTX-RML) is a type of therapy-related lymphoma, and it often occurs in patients with rheumatoid arthritis. The most distinctive characteristic of MTX-RML is a quick response to withdrawal of MTX. However, because there is a risk of recurrence without a distinctive indicator of disease, close follow-up is needed. We present F-18 2-fluoro-2-deoxyglucose (FDG) postitron emission tomography (PET) or computed tomography (CT) images of MTX-RML along with the characteristic clinical presentation of MTX-RML. FDG PET/CT has the advantage of being able to detect malignant lymphoma in patients who have undergone MTX treatment. After withdrawal of MTX, FDG uptake decreases along with a reduction in the volume of lesions. Although recurrent lesion develops independent to the initial FDG PET/CT findings, FDG PET/CT is useful for early detection of unexpected recurrent lesions. FDG PET/CT allows for the assessment of malignant lymphoma and recurrent lesions in patients who received MTX therapy, which is crucial for the management of MTX-RML.
Subject(s)
Fluorodeoxyglucose F18 , Lymphoma/chemically induced , Lymphoma/diagnostic imaging , Methotrexate/adverse effects , Tomography, X-Ray Computed , Adult , Aged , Female , Humans , Male , Middle Aged , Radionuclide Imaging , Whole Body ImagingSubject(s)
Fluorodeoxyglucose F18 , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/drug therapy , Heparin/therapeutic use , Lymphoma/diagnostic imaging , Lymphoma/drug therapy , Positron-Emission Tomography/methods , Aged , Anticoagulants/therapeutic use , Female , Humans , Radiopharmaceuticals/therapeutic use , Subtraction Technique , Tomography, X-Ray Computed/methodsABSTRACT
Myxofibrosarcoma (MFS) has a spectrum of malignant fibroblastic lesions with variably myxoid stroma and pleomorphism. A 67-year-old man with a bulky mass on his chest wall was diagnosed with MFS. He underwent F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography for detection of metastasis. FDG positron emission tomography /computed tomography showed inhomogeneous high FDG uptake (max standardized uptake value, 10.1) in the bulky tumor with no evidence of metastasis, and the tumor was successfully resected. FDG uptake seemed to be reflected by the broad spectrum of pathologic heterogeneity. And MFS should be considered when making a diagnosis of inhomogeneous FDG-avid lesions in the bulky masses of soft tissue.
Subject(s)
Fibrosarcoma/diagnostic imaging , Fluorodeoxyglucose F18 , Myxosarcoma/diagnostic imaging , Positron-Emission Tomography , Thoracic Wall/diagnostic imaging , Tomography, X-Ray Computed , Aged , Fibrosarcoma/complications , Humans , Male , Myxosarcoma/complications , Whole Body ImagingABSTRACT
We present two cases of tuberculous pericarditis that were diagnosed using 18F-fluorodeoxyglycose (18F-FDG) positron emission tomography (PET). Here, we highlight the value of 18F-FDG-PET for demonstrating tuberculous pericardial involvement as well as disease dissemination and activity. The patients received antitubercular treatment, and their symptoms and findings resolved accordingly.
